The Strange Case of BCG and COVID-19: The Verdict Is Still up in the Air.
The Strange Case of BCG and COVID-19: The Verdict Is Still up in the Air.
复制标题
DOI：
10.3390/vaccines8040612
复制
发表时间：
2020-10-16
期刊：
影响因子：
7.8
通讯作者：
Subbian S
中科院分区：
文献类型：
--
作者：
Gopalaswamy R;Ganesan N;Velmurugan K;Aravindhan V;Subbian S
COVID-19由一种新型冠状病毒SARS-CoV-2引起，是全球人类发病率和死亡率的重要原因。在缺乏特定疫苗或治疗方法的情况下，COVID-19病例通过被动免疫方法和将用于其他疾病的药物重新利用来经验性地管理。最近，出现了卡介苗（BCG）疫苗接种可以预防COVID-19的概念。这种广泛关注的基础来自最近的几篇文章，包括米勒等人提交给MedRxiv（一个预印本服务器）的一篇文章。这篇文章的作者认为，长期实施全国卡介苗接种计划的国家与COVID-19的发病率/死亡率之间存在相关性。此外，荷兰、澳大利亚、英国和德国目前正在进行BCG疫苗接种临床试验，以期降低COVID-19导致的死亡率。虽然卡介苗接种有助于保护儿童免受结核病的侵害，但实验研究表明，卡介苗也可以引发针对病毒和非分枝杆菌感染的非特异性免疫反应。在这里，我们总结了卡介苗接种的利弊，并批判性地分析了卡介苗对COVID-19的保护作用的证据，并强调了这些研究中的混杂因素。
COVID-19, caused by a novel coronavirus, SARS-CoV-2, contributes significantly to the morbidity and mortality in humans worldwide. In the absence of specific vaccines or therapeutics available, COVID-19 cases are managed empirically with the passive immunity approach and repurposing of drugs used for other conditions. Recently, a concept that bacilli Calmette–Guerin (BCG) vaccination could confer protection against COVID-19 has emerged. The foundation for this widespread attention came from several recent articles, including the one by Miller et al. submitted to MedRxiv, a pre-print server. The authors of this article suggest that a correlation exists between countries with a prolonged national BCG vaccination program and the morbidity/mortality due to COVID-19. Further, clinical BCG vaccination trials are currently ongoing in the Netherlands, Australia, the UK, and Germany with the hope of reducing mortality due to COVID-19. Although BCG vaccination helps protect children against tuberculosis, experimental studies have shown that BCG can also elicit a non-specific immune response against viral and non-mycobacterial infections. Here, we summarize the pros and cons of BCG vaccination and critically analyze the evidence provided for the protective effect of BCG against COVID-19 and highlight the confounding factors in these studies.
登录
查看更多内容
影响因子：
7.8
作者：
Klinger D;Blass I;Rappoport N;Linial M
通讯作者：
Linial M
DOI：
10.1073/pnas.92.23.10693
发表时间：
1995-11-07
影响因子：
11.1
作者：
HONDA, M;MATSUO, K;YAMAZAKI, S
通讯作者：
YAMAZAKI, S
DOI：
10.1016/j.clim.2014.10.005
发表时间：
2014-12
期刊：
Clinical immunology (Orlando, Fla.)
影响因子：
--
作者：
Kleinnijenhuis J;Quintin J;Preijers F;Joosten LA;Jacobs C;Xavier RJ;van der Meer JW;van Crevel R;Netea MG
通讯作者：
Netea MG
影响因子：
--
作者：
Hayward, Sally;Harding, Rosalind M;Tanner, Rachel
通讯作者：
Tanner, Rachel
影响因子：
5.5
作者：
Harboe, M;Andersen, P;Kaufmann, SHE
通讯作者：
Kaufmann, SHE